EGFR and autoimmune polyendocrine syndrome type 1: This knowledge could pave the way for targeted therapies, including EGFR inhibitors, STAT3 blockade or immune checkpoint modulation, tailored to the particular immune landscape of APS-1 [80,81,82,83,84].